The adage “a rising tide lifts all boats” may soon be put to the test in the stock market as a bull market continues to surge forward. While the S&P 500 has seen impressive gains of over 30% in the last 12 months, not every stock has experienced the same level of success. However, two Motley Fool contributors believe they have identified some hidden gems that are still trading down 30% or more from their 52-week highs.
One such stock is Pfizer, which has seen its stock price drop by 34% over the past year. Despite the challenges the company has faced with declining demand and upcoming patent expirations, Pfizer is poised for a potential turnaround. With a record number of product approvals last year and a strategic focus on oncology through its acquisition of Seagen, Pfizer is expected to see significant revenue growth in the coming years.
Similarly, Moderna has also seen its stock price plummet by 35% over the last 12 months due to COVID-19 headwinds. However, with the anticipated approval of its respiratory syncytial virus (RSV) vaccine mRNA-1345 and a promising pipeline of other vaccines, Moderna is projected to return to organic sales growth by 2025.
While there are no guarantees in the stock market, both Pfizer and Moderna appear to have promising futures ahead. Investors may want to consider these stocks as potential opportunities for growth in the coming months and years.
